
Catalog: #2416

Store at: -20ºC


For Research Use Only. Not For Use In Diagnostic Procedures.

Applications Flow Cytometry,WB	Detection Anti-Rabbit IgG	Clonality Monoclonal	lsotype Rabbit IgGk		
Format:	Unconjugated				
Cross Reactivity:	Predicted to work with mouse, rat and	l other homologues.			
Formulation:	1X PBS, 0.02% NaN3, 50% Glycerol, 0	.1% BSA			
Preparation:	Protein A+G				
Reactivity:	Human,Mouse				
Recommended Usage:	1μg/mL – 0.001μg/mL. It is recommen optimal performance for each applica additional information.				
Immunogen:	A synthetic phospho-peptide correspo human phospho Lyn	onding to residues surro	unding Tyr507 of		
Description:	Lyn, along with Btk, supports the abne mast cells. Phosphorylated Lyn has be along with phosphorylated Btk, Hck, a used to treat leukemia, is a tyrosine k neoplastic cells. Lyn and Btk have also receptor-dependent activation. Increa amounts of phospho Lyn, has been de This is likely mediated through effects than mutations in Lyn itself.	een identified in these cand Stat5. Dasatinib, a c inase inihibitor that bind o been shown to be invo used Lyn activity, detect emonstrated in breast ca	ancerous cells, chemotherapy drug ds directly to Lyn in plved in IgE red by higher ancer cell lines.		
References:	Gleixner KV, Mayerhofer M, Cerny-Rei Choi Y, Bocanegra M, Kwon MJ et al. (2 70: 2296-2306.				






Flow cytometric analysis of Jurkat cells secondary antibody only negative control (blue) or untreated (red) or treated with IFN α + IL-4 + pervanadate (green) using Phospho-Lyn (Tyr507) antibody LynY507-5B6 at 0.01 μ g/mL. Cat. #2416.




lgG	Treatment	Peptide Block	Median : BL1-A
5B6	IFNaIL4Pv	Non-Phos.	65561
5B6	Ctrl	Non-Phos.	2851
5B6	IFNaIL4Pv	Phospho.	231
5B6	Ctrl	Phospho.	217
5B6	IFNaIL4Pv	-	69140
5B6	Ctrl	-	3169
2' only	Ctrl	-	116

Peptide blocking flow cytometric analysis of Jurkat cells secondary antibody only negative control (light blue) or untreated (red) or treated with $IFN\alpha + IL-4 + pervanadate$ (green) or untreated and blocked with phospho-peptide (black) or treated and blocked with phospho peptide (gold) or untreated and blocked with non-phospho peptide (dark blue) or treated and blocked with non-phospho peptide (purple) using Phospho-Lyn (Tyr507) antibody LynY507-5B6 at 0.01µg/mL. Cat. #2416.






Flow cytometric analysis of C2C12 cells secondary antibody only negative control (blue) or treated with imatinib (red) or with pervanadate (green) using Phospho-Lyn (Tyr507) antibody LynY507-5B6 at 0.01µg/mL. Cat. #2416.




Western blot analysis of extracts of HeLa cells treated with H2O2. Cell lysates were ran on a SDS-PAGE gel, transferred to nitrocellulose membrane, blocked and non-treated (-) or treated with lambda phosphatase (+) and stained using anti-phosph-Lyn (Tyr507) 5B6 rabbit recombinant antibody #2416.





Western blot analysis of Hela cell extract, untreated or treated with H2O2 using Phospho-LYN(TYR507) antibody LYNY507-5B6 at 0.01 ug/mL. Cat. #2416.





Western blot analysis of HeLa cell extract, untreated or treated with H2O2 using 0.01 μ g/mL Phospho-Lyn (Tyr507) antibody LynY507-5B6 Cat. #2416 or Company A antibody at 1 μ g/mL (manufacturer's recommended concentration) developed using the same exposure.

